Nutriband Inc., a developer of prescription transdermal pharmaceutical products, has announced a strategic partnership with Brand Institute, Inc. to create the worldwide commercial brand name and visual identity for AVERSA FENTANYL, the company's lead product utilizing its proprietary AVERSA abuse-deterrent transdermal technology. This collaboration marks a significant step toward commercializing what could become the world's first abuse-deterrent opioid patch designed specifically to deter misuse and reduce accidental opioid exposure.
The partnership brings together Nutriband's innovative pharmaceutical technology with Brand Institute's extensive expertise in pharmaceutical branding. Brand Institute holds a dominant position in the pharmaceutical naming industry, with a 75% share of global drug name approvals and an impressive 87% of FDA-approved names in 2024. The initiative will be conducted in collaboration with Brand Institute's regulatory subsidiary, Drug Safety Institute, which employs former officials from major regulatory bodies including the FDA, EMA, Health Canada, USAN, and WHO.
AVERSA FENTANYL represents a critical advancement in opioid safety technology. The AVERSA technology, developed by Nutriband's subsidiary 4P Therapeutics, can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. This technology addresses a significant public health concern surrounding opioid medications, particularly transdermal delivery systems that have historically been vulnerable to misuse.
The development of a comprehensive global brand identity for AVERSA FENTANYL through this partnership with Brand Institute is essential for the product's commercial success and market recognition. Proper branding and regulatory-compliant naming are crucial elements in the pharmaceutical industry, where product identification and safety communication play vital roles in patient care and medication management. More information about Nutriband can be found at https://www.nutriband.com.
This collaboration comes at a time when the opioid crisis continues to be a major public health concern globally. The development of abuse-deterrent formulations represents an important strategy in combating prescription drug misuse while maintaining access to necessary pain management options for legitimate patients. The involvement of regulatory experts through Drug Safety Institute ensures that the branding process will navigate complex international regulatory requirements effectively, potentially accelerating the product's path to market approval across multiple jurisdictions.
